Loading
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Previous close
$44.50
−$0.36 · -0.80%
Regular session · ET · Market data may be delayed.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Day range
Current $44.50
52-week range
Current $44.50
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
62
Bullish
Risk
58
Elevated Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Day range
Current $44.50
52-week range
Current $44.50
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 16.1M USD | 27.12M USD | 15.84M USD | 106.48M USD | 524M USD |
| Cost of goods sold | 1.69M USD | 18.33M USD | 13.63M USD | 3.34M USD | 24.98M USD |
| Gross profit | 14.41M USD | 8.79M USD | 2.22M USD | 103.14M USD | 499.03M USD |
| Research and development | 140.67M USD | 143.78M USD | 214.86M USD | 197.59M USD | 143.55M USD |
| Selling, general, and administrative | 65.34M USD | 50.68M USD | 73.08M USD | 54.7M USD | 56.29M USD |
| Operating expenses | 202.24M USD | 193.09M USD | 285.09M USD | 246.3M USD | 188.41M USD |
| Interest income | 16.97M USD | 21.42M USD | 19.56M USD | 609K USD | 162K USD |
| Interest expense | 61.99M USD | 63.74M USD | 41.56M USD | 11.7M USD | 7.47M USD |
| Depreciation and amortization | 14.76M USD | 12.64M USD | 11.9M USD | 8.54M USD | 7.3M USD |
| Operating income | −187.83M USD | −184.29M USD | −282.87M USD | −143.16M USD | 310.62M USD |
| Net income | −198.97M USD | −239.56M USD | −308.48M USD | −126.79M USD | 329.59M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$57.50
29.21% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI114.35M1.00%11.49B USD0.35%$163.81-0.35%
Vanguard Extended Market ETFVXF34.18M0.04%93.7B USD0.05%$242.66+0.14%
Schwab U.S. Small-Cap ETFSCHA14.37M0.06%22.56B USD0.03%$34.55+1.01%
First Trust Small Cap Growth AlphaDEX FundFYC7.4M0.52%1.43B USD0.70%$119.54+0.04%
Vanguard Health Care ETFVHT6.2M0.03%20.9B USD0.09%$321.66-0.97%
Invesco Dorsey Wright Healthcare Momentum ETFPTH4.16M1.45%285.5M USD0.74%$61.1284-0.38%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP3.92M0.15%2.67B USD0.20%$67.695+0.29%
Direxion Daily S&P Biotech Bull 3X SharesLABU3.81M0.66%584.65M USD0.96%$303.55-0.76%State Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAFirst Trust Small Cap Growth AlphaDEX FundFYCVanguard Health Care ETFVHTInvesco Dorsey Wright Healthcare Momentum ETFPTHState Street SPDR S&P Kensho New Economies Composite ETFKOMPDirexion Daily S&P Biotech Bull 3X SharesLABUAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
